Delisting risk
GT Biopharma (GTBP)
Developer of natural-killer-cell engagers for cancer and autoimmune disease.
$0.2833
At close−0.01 (−1.94%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions58 holders · as of Jun 30, 2026 | 4.70% | 2.12M shares | |
| Insiders1 holder · as of Feb 5, 2019 | 0.02% | 9.2K shares | |
| Strategic holders2 holders · as of Dec 4, 2017 | 0.02% | 7.3K shares | |
| Otherremainder | 95.26% | 42.97M shares |
45.11M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (45.11M in the company's Sep 3, 2026 report, 31.55M elsewhere); stakes use the report.
Institutions13F, as of Jun 30, 2026
58 holders · 2.12M shares · 24 new positions · 32 increased · 8 reduced · 5 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Vanguard Capital Management LLC | 376.4K | 0.83% | −75.5K | Aug 13, 2026 |
| Geode Capital Management, LLC | 266.8K | 0.59% | −27.7K | Aug 12, 2026 |
| Vanguard Fiduciary Trust Co | 225.9K | 0.50% | 0 | Aug 13, 2026 |
| HRT Financial LP | 107.1K | 0.24% | +107.1K | Aug 14, 2026 |
| Everhart Financial Group, Inc. | 100.0K | 0.22% | +100.0Knew | Jul 9, 2026 |
| SRS Capital Advisors, Inc. | 93.6K | 0.21% | 0 | Aug 10, 2026 |
| Opal Wealth Advisors, LLC | 81.8K | 0.18% | +81.8Knew | Jul 20, 2026 |
| Northern Trust Corp | 75.5K | 0.17% | +75.5Knew | Aug 13, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Five Narrow Lane LP | 9.99% | 13G | May 14, 2025 ↗ |
Insider tradesForm 4
Latest trades
No open-market trades in the last 12 months.
CongressHouse and Senate disclosures
Not reported.